Novartis
See the following -
3 Reasons Why Pharma mHealth Apps Have Failed
Pharma mHealth companies are struggling to have an impact on the mHealth app market generating only limited downloads and usage, despite releasing more than 100 pharma mHealth apps for iOS and Android...
- Login to post comments
7 Google Ventures Poised To Revolutionize Healthcare
Forget the “sky’s the limit.” Google is reaching for the moon when it comes to healthcare innovation...
- Login to post comments
A Law Professor’s Big Idea for Combating Greedy Drug Company Titans Like Martin Shkreli
In 2015, CEO of Turing Pharmaceuticals Martin Shkreli infamously raised the price of the life-saving drug Daraprim by 5,000%. Daraprim, developed more than 60 years ago, is used to treat the deadly parasitic infection toxoplasmosis. It was selling for $13.50 a pill; then Turing raised the price to $750. The move sparked massive backlash and Congressional hearings, and Shkreli himself was eventually arrested for, and convicted of, unrelated securities fraud charges. But the original, horrible problem didn’t get fixed. Turing kept the price sky-high; as of August 2016, many patients were paying $375 per pill...
- Login to post comments
European Bioinformatics Institute (EMBL-EBI) ChEMBL 20 incorporates the Pistoia Alliance’s HELM annotation
The European Bioinformatics Institute (EMBL-EBI) has released version 20 of ChEMBL, the database of compound bioactivity data and drug targets. ChEMBL now incorporates the Hierarchical Editing Language for Macromolecules (HELM), the macromolecular representation standard recently released by the Pistoia Alliance.
- Login to post comments
Expensive Drugs Forcing Cancer Doctors To Weigh Price
...With new cancer drugs priced as high as $10,000 a month and more, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
- Login to post comments
Is Shkreli the Exception, or the Norm, in Big Pharma?
I didn't want to write about pharmaceutical companies. They get enough bad press, and adding to it almost seems like piling on. If Valeant is the poster company for outrage about drug pricing, it's less because what they are doing is unusual than it is because we suspect they are the norm. Honestly, I wanted to discuss McDonald's turning their Happy Meals boxes into VR headsets --I'm not making that up -- but, gosh darn it, it's almost like the pharmaceutical companies are daring me to talk about them. So I will.
- Login to post comments
Merck To Bristol-Myers Face Threats On India Patents (Correct)
Pharmaceutical companies from Merck & Co. (MRK:US) to Bristol-Myers Squibb Co. (BMY:US) face fresh threats to protecting their patents in India as a government-appointed panel prepares to evaluate more drugs for local makers to copy. The panel is looking beyond the cancer treatments it studied last year to areas such as HIV and diabetes, according to two people with knowledge of the matter, who asked not to be identified because the discussions are private.
- Login to post comments
Novartis Trials Patients Know Best
Pharmaceutical firm Novartis is to begin a post-market trial using the online patient-controlled personal health records service supplied by Patients Know Best. Post-market trials are conducted for drugs that have passed initial toxicity and effectiveness tests and received some regulatory approval. Read More »
- Login to post comments
On the Financial Conflicts of Interests of Medical Societies and Rising Drug Prices
The notion that health care prices are high and are rising continuously in the US should hardly be novel...We first posted about high drug prices in July, 2005, with the example of BilDil...But only a few days later we noted that three cancer costs had yearly costs in the five figures, and one, Erbitux, cost as much as $100,000. Most amazingly we noted that Thalidomid was priced at $25,000 a year...Since then, the ridiculously high prices of many tests and treatments, but most notably new drugs and devices, has been so widely covered, our discussion has been limited to special cases.,,
- Login to post comments
Open Source Drug Discovery Test A Success
In what is being called the first-ever test of open-source drug-discovery, researchers from around the world have successfully identified compounds to pursue in treating and preventing parasite-borne illnesses such as malaria as well as cancer...One-third of the labs reported their results in a paper published today in PLOS Pathogens, "Open source drug discovery with the Malaria Box compound collection for neglected diseases and beyond." The results have ignited more a dozen drug-development projects for a variety of diseases. "The trial was successful not only in identifying compounds to pursue for anti-malarials, but it also identified compounds to treat other parasites and cancer," said lead author Wesley Van Voorhis.
- Login to post comments
Open-access R&D for Drug Industry
LONDON: Drug companies are learning how to share. In a bid to save both time and money, some of the industry’s biggest names are experimenting with new ways to pool early-stage research, effectively taking a leaf out of the “open-source” manual that gave the world Linux software. Read More »
- Login to post comments
The Evolving Landscape Of Medical Apps In Healthcare
Mitchell Posada, VP of Marketing at Pathfinder Software discusses the evolving landscape of medical apps in healthcare...
- Login to post comments
Universal Language: The Pistoia Alliance Takes on Indescribable Biology
Best Practices WinnerThe Pistoia Alliance has previously sponsored new methods for querying databases and the scientific literature, and a more effective algorithm for compressing and sharing genetic sequencing data. Over the past year, another Pistoia project, HELM, has entered the public domain after gradual development by an assortment of Alliance members. An open source language and set of editing tools for working with large biomolecules, HELM has already become a foundational part of research in at least three large pharmaceutical companies. Read More »
- Login to post comments
What Clinical Trial Results? Now You Can See Who Isn’t Sharing Their Findings
The results for nearly half of all clinical trials conducted by big drug makers during the last decade have not been published, and one company — Ranbaxy Laboratories — has not published findings for any of the nearly three dozen trials conducted in the past 10 years, according to a new online tool. The tool was launched Thursday by AllTrials, a consortium of researchers and medical journals that has been pushing the pharmaceutical industry to do a better job of disclosing clinical trial data...
- Login to post comments
You Won't Believe the Outrageous Ways Big Pharma Has Bribed Doctors to Shill Drugs
At the 2010 meeting of the American Psychiatric Association in New Orleans, a psychiatrist from the East coast shared her anger with me about the recent clamp down on Pharma financial perks to doctors. Before news organizations and the 2010 Physician Financial Transparency Reports (also called the Sunshine Act, part of the Affordable Care Act) reported the outrageous amount of money Pharma was giving doctors to prescribe its new, brand-name drugs, there was almost no limit to what was spent to encourage prescribing...
- Login to post comments